RxDoctor Payments Data

Lisa Mills, MD

Hematology & Oncology · Berkeley Heights, NJNPI 1215052287

Payments from drug & device makers

$183in general payments, 2019–2025

Across 8 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$68
  • Novartis$35
  • Johnson & Johnson$28
  • Regeneron Healthcare Solutions, Inc.$14
  • Eisai Inc.$14
  • Pfizer$13
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$11563%
  • Education$6837%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$183 in reported general payments places this provider in the 10th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$2,635,948
Medicare patients
563
Services billed
129,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib26$408,472
TasignaNilotinib Hcl20$363,316
Lenalidomide23$327,184
JakafiRuxolitinib Phosphate17$286,183
CalquenceAcalabrutinib Maleate17$259,533
BrukinsaZanubrutinib18$250,883
RevlimidLenalidomide14$246,364
TagrissoOsimertinib Mesylate12$203,938
ImbruvicaIbrutinib12$190,705
VerzenioAbemaciclib12$183,593
EliquisApixaban109$118,985
XareltoRivaroxaban73$81,556
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$61,831
Imatinib Mesylate15$57,144
Anastrozole276$7,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$13$527,457135 claims
AstraZenecaCalquence, Tagrisso$68$463,47129 claims
NovartisTasigna$35$363,31620 claims
Lilly USA, LLCVerzenio$11$183,59312 claims
Johnson & JohnsonXarelto$28$81,55673 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 362 hematology & oncology providers in New Jersey.

Other hematology & oncology in Berkeley Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →